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Drug resistance in tuberculosis predominantly, mono-resistance, multi drug resistance,
extensively drug resistance and totally drug resistance have emerged as a major
problem in the chemotherapy of tuberculosis. Failures of first and second line
anti-tuberculosis drugs treatment leads to emergence of resistant Mycobacterium
tuberculosis. Few genes are reported as the principal targets of the resistance and apart
from the primary targets many explanations have been proposed for drug resistance
but still some resistance mechanisms are unknown. As proteins involved in most
of the biological processes, these are potentially explored the unknown mechanism
of drug resistance and attractive targets for diagnostics/future therapeutics against
drug resistance. In last decade a panel of studies on expression proteomics of drug
resistant M. tuberculosis isolates reported the differential expression of uncharacterized
proteins and suggested these might be involved in resistance. Here we emphasize
that detailed bioinformatics analysis (like molecular docking, pupylation, and proteins-
proteins interaction) of these uncharacterized and hypothetical proteins might predict
their interactive partners (other proteins) which are involved in various pathways of
M. tuberculosis system biology and might give a clue for novel mechanism of drug
resistance or future drug targets. In future these uncharacterized targets might be open
the new resistance mechanism and used as potential drug targets against drug resistant
tuberculosis.
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INTRODUCTION
Current Scenario
Tuberculosis (TB) still remains one of the deadliest infectious diseases worldwide which is caused
by Mycobacterium tuberculosis. WHO reported 10.4 million people became ill and that 1.8 million
died from TB (WHO, 2016). For controlling this situation the available current tools are vaccine
diagnostics and drugs. Over the past 50 years, the Mycobacterium bovis bacille Calmette–Guérin
(BCG) vaccine against TB has maintained its position as the world’s most widely used vaccine,
despite showing highly variable efficacy (0–80%) in different trials (Andersen and Doherty, 2005).
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Sputum smear microscopy is the most common TB diagnostic
method worldwide. However, culture remains the gold standard
and the use of rapid molecular testing like line probe
assay (LPA) is increasing for detection of drug resistant
M. tuberculosis strains. Recently in India, Revised National
TB Control Program (RNTCP) has approved a study for
the Validation of second line LPA for detecting resistance
to fluoroquinolones, aminoglycosides (kanamycin, amikacin),
and cyclic peptides (capreomycin). First and second line
drugs are the effective and necessary component of short
course chemotherapy. DOTS and DOTS plus program have
reduced the incidence of TB caused by susceptible strain
but emergence of multidrug-resistant tuberculosis (MDR-TB),
extensively drug resistant tuberculosis (XDR-TB), and totally
drug resistant tuberculosis (TDR-TB) have worsened the
situation and became a major threat to public health. Current
tools (vaccines, diagnostics, and therapeutics) are unable to
offer the complete protection against these deadly drug resistant
situations.
Mystery behind the Drug Resistance
Usually interrupted anti-TB drugs treatment (first and second
line anti-mycobacterial drugs) leads to emergence of drug
resistant M. tuberculosis strains. Probably these resistant
M. tuberculosis strains can resist antibiotic actions by the series
of mechanisms such as: mutations in target genes (Beauclerk and
Cundliffe, 1987), enzymatic inactivation of antibiotic molecules
(Welch et al., 2005), over expression of novel eﬄux pumps
and porin alterations in the cell wall (Magnet et al., 2001;
Nikaido, 2003), trapping of drugs and the over expression of
proteins involved in neutralizing the effect of drugs (Magnet
et al., 2003; Kumar et al., 2013; Lata et al., 2015a; Sharma
et al., 2015a, 2016b). Genes involved in these drug resistance
mechanisms are tabulated in Table 1 (adopted from Zhang
and Yew, 2009 and updated). Figure 1 is the schematic
diagram which showed the potential mechanism (s) of action
of first line (Rifampicin-inhibition of RNA synthesis, Isoniazid-
inhibition of mycolic acid biosynthesis, Ethambutol-inhibition of
arabinogalactan synthesis, Pyrazinamide-depletion of membrane
energy, and Streptomycin-inhibition of protein synthesis)
and second line of anti-TB drugs (Amikacin, Kanamycin,
Capreomycin-inhibition of protein synthesis and Quinolones-
inhibition of DNA gyrase) and the potential mechanism (s)
of drug resistance, respectively. These mechanisms of action
of drugs were also tabulated in Table 1. Usually 36–95%
resistances in M. tuberculosis were contributed by mutations
in the target genes, however, remaining 5–64% does not
have these mutations and signifying the contribution of some
other resistance mechanism (s). Research through expression
proteomics (2D gel electrophoresis) and bioinformatic tools
(like molecular docking, pupylation, and proteins-proteins
interaction) explored the other novel mechanisms of drug
resistance were accumulated in last decade and still underway.
Patch dock and fire dock (molecular docking) predicted,
drug binds to the conserved domain of the hypothetical
proteins and suggested that overexpression of these proteins
of undefined role might be neutralize/modulate the effects
of drugs (Sharma et al., 2015a, 2016b). Pupylation is a post
translational modification through which small disordered
protein Pup is conjugated to lysine residues of proteins marking
them for proteasomal degradation. GPS-PUP (pupylation)
predicted, that neutralized/modulated adduct (drug-protein
complex) might be degraded by proteasome machinery complex
{turnover of the proteins} (Sharma et al., 2015a, 2016b). As
modification with pup is reversible, pupylation is also likely
to have a regulatory role. Pup-proteasome system controlled
by pupylation contributes to the virulence/survival strategy of
M. tuberculosis in the host and makes the bacteria more resistant
to various stresses. STRING-10 (Proteins-proteins interaction)
predicted the potential interactive partners and suggested the
metabolic pathways involved in resistance (Sharma et al.,
2016a,b). Rv0148 (hypothetical protein/putative short-chain type
dehydrogenase/reductase) was overexpressed in aminoglycosides
resistant M. tuberculosis and had conserved SDR domain. We
found that aminoglycosides binds to SDR domains and might
be neutralized the drug effect (Sharma et al., 2015a). Further
we characterized it and found that overexpression of Rv0148
involved in shift in MIC of aminoglycosides in recombinant
E. coli (Sharma et al., 2015b). These findings might be used in the
development of newer therapeutic agents or molecular markers
which can directly be targeted to a gene/protein responsible for
resistance. In this work we discuss the probable involvement
of uncharacterized/hypothetical proteins (differential expression
in drug resistance studies were previously reported) in drug
resistance via bioinformatics analysis (like molecular docking,
pupylation, and proteins-proteins interaction) and suggested that
these might be explore novel mechanism of drug resistance or
used as potential future drug target/diagnostics against drug
resistance.
Expression Proteomics and
Bioinformatics Approaches: A Way for
Exploring the Mystery of Drug
Resistance
Advancement in proteomics has explored the mystery behind
any complex phenotypes like drug resistance. As proteins
manifest most of the biological processes, these are attractive
targets for exploring new mechanisms of the drug resistance.
Expression proteomics (2-DE coupled with MALDI-TOF-MS)
and bioinformatic tools {patch dock and fire dock for molecular
docking, GPS-PUP for pupylation, and STRING-10 for protein-
protein interaction} have now emerged as major analytical tools
for identification and characterization of expression proteome
(proteins and its species) (Sharma et al., 2015a; Sharma and
Bisht, 2016). In the last decade (2006–2016) few reports
on expression proteome of drugs resistant M. tuberculosis
existed (Jiang et al., 2007; Sharma et al., 2010, 2014, 2015b,
2016b; Kumar et al., 2013; Lata et al., 2015a,b; Singh et al.,
2015; Sharma and Bisht, 2017) and suggested that differential
expression of functionally known and unknown proteins
and their protein-protein interaction might be involved in
resistance and could be explore the novel mechanism of
resistance.
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TABLE 1 | Mechanisms of genes involved in drug resistance in Mycobacterium tuberculosis.
Drug (Year of
discovery)
MIC (µg/ml) Gene (s) involved
in resistance
Gene-product Mechanism of action Mutation
frequency %
Isoniazid, 1952 0.02–0.2 katG inhA Catalase-peroxidase Enoyl
ACP reductase
Inhibition of mycolic
acid biosynthesis and
other multiple effects
50–95 8–43
Rifampicin, 1966 0.05–1 rpoB β-subunit of RNA
polymerase
Inhibition of RNA
synthesis
95
Pyrazinamide, 1952 16–50 (pH 5.5) pncA Nicotinamidase/
pyrazinamidase
Depletion of membrane
energy
72–97
Ethambutol, 1961 1–5 embB Arabinosyl transferase Inhibition of
arabinogalactan
synthesis
47–65
Streptomycin, 1944 2–8 rpsL rrs gidB S12 ribosomal protein 16S
rRNA rRNA
methyltransferase
Inhibition of protein
synthesis
52–59 8–21 ?
Amikacin Kanamycin,
1957; Capreomycin,
1960
2–4 Rrs tlyA 16S rRNA
2′-O-methyltransferases
Inhibition of protein
synthesis
76
Quinolones, 1963 0.5–2.5 gyrA gyrB DNA gyrase subunit A DNA
gyrase subunit B
Inhibition of DNA
gyrase
75–94
Ethionamide, 1956 2.5–10 ethA Flavin monooxygenase Inhibition of mycolic
acid synthesis
37
PAS, 1946 1–8 thyA Thymidylate synthase Inhibition of folic acid
synthesis and iron
metabolism
36
Bedaquiline, 2012 0.125–0.50 atpE ATP synthase Block the proton pump
for ATP synthesis
?
MIC, minimum inhibitory concentration; ACP, acyl carrier protein; PAS, Para-aminosalicylic acid.
FIGURE 1 | Schematic diagram showed: (A) Potential mechanism (s) of action of first and second line of anti-TB drugs. (B) Potential mechanism (s) of drug
resistance in Mycobacterium tuberculosis.
Frontiers in Microbiology | www.frontiersin.org 3 March 2017 | Volume 8 | Article 465
fmicb-08-00465 March 17, 2017 Time: 17:28 # 4
Sharma and Bisht Exploring Resistance Mechanism of M. tuberculosis
HYPOTHETICAL PROTEINS AND
PROTEINS OF UNKNOWN FUNCTION:
POTENTIAL TARGETS OF DRUG
RESISTANCE OR NOVEL RESISTANCE
MECHANISMS
Since last decade, few proteomics and bioinformatics studies
of drug resistant M. tuberculosis have been accumulated and
reported the differential expression of a panel of uncharacterized
(proteins of unknown function) and hypothetical proteins.
Through in silico/bioinformatic (Interproscan and molecular
docking) analysis they showed that drugs binds to the conserved
domains of hypothetical proteins/uncharacterized proteins and
suggested that the over expression of a panel of uncharacterized
and hypothetical proteins might neutralize/compensate the effect
of drugs. Sharma et al. (2015b, 2016a) reported that inducible
over expression of cloned known and unknown proteins
(Rv0148 and Rv3841) in E. coli makes it two- to threefolds
more resistant under drug pressure. Here we emphasize that
detailed bioinformatics analysis (like protein-protein interaction)
of these uncharacterized and hypothetical proteins might
predict their interactive partners (other proteins) which are
involved in various pathways of M. tuberculosis system biology
(exploring/deciphering the M. tuberculosis network biology
through in silico/holistic approaches) and might give a clue for
novel mechanism of drug resistance or future target. Research in
this direction could prevent the emergence of MDR-TB, XDR-
TB, and TDR-TB situation and also these targets may be used
to discover the new drug entities as potential drug candidates
against drug resistant tuberculosis.
CONCLUSION AND FUTURE
PERSPECTIVE
Based on the evidence discussed above related to expression
proteomics and bioinformatics studies of drug resistant
M. tuberculosis have been reported the differential expression
of uncharacterized and hypothetical proteins (Jiang et al.,
2007; Sharma et al., 2010, 2014, 2015b, 2016b; Kumar et al.,
2013; Lata et al., 2015a; Singh et al., 2015; Sharma and Bisht,
2017). Molecular docking analysis of these uncharacterized
and hypothetical proteins suggested that their over expression
might neutralize/compensate the effect of drugs (Sharma
et al., 2010, 2015a, 2016b; Kumar et al., 2013; Lata et al.,
2015a; Sharma and Bisht, 2017) which further proved by
other reports and showed inducible over expression of cloned
known and unknown proteins in E. coli which makes it
few folds more resistant under drug pressure (Sharma et al.,
2015b). Here we emphasized the detailed in silico analysis
through patch dock, fire dock (molecular docking), GPS-
PUP (pupylation), and STRING-10 (predicts the proteins-
proteins interactions/interactome) of these uncharacterized
and hypothetical proteins which might be involved in various
pathways of M. tuberculosis system biology (Lata et al.,
2015a; Sharma et al., 2015a, 2016b; Sharma and Bisht,
2017). Future research in this direction could be uncovering
the novel mechanism of drug resistance or future target.
Which ultimately prevent the emergence of deadly resistant
strains of M. tuberculosis and could leads to discovery
of the new drug entities against deadly drug resistant
tuberculosis.
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